What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing up or down? Are biopharma companies outsourcing more or less? Plus the impact on evolving trade policy on biomanufacturing supply chains. 

Featuring: Eric Langer, MBA, Managing Partner & President, BioPlan Associates and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan Associates

Support the show